CC
TVTX icon

Corton Capital’s Travere Therapeutics TVTX Stock Holding History

Corton Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,732
Closed -$159K – 406
2025
Q2 		$159K Buy
+10,732
New +$178K 0.18% 272
2024
Q1 		– Sell
-16,584
Closed -$149K – 658
2023
Q4 		$149K Sell
16,584
-13,212
-44% -$96.2K 0.05% 515
2023
Q3 		$266K Buy
+29,796
New +$420K 0.13% 227
2022
Q1 		– Sell
-13,349
Closed -$414K – 491
2021
Q4 		$414K Buy
+13,349
New +$376K 0.18% 116

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Corton Capital's TVTX Position: Q3 2025 in Review

Corton Capital sold out of Travere Therapeutics (TVTX) in Q3 2025, closing a stake of 10,732 shares — an estimated $159K sold.

Corton Capital first reported a position in TVTX in Q4 2021 and held it in 4 quarters. The position peaked at $414K in Q4 2021. 238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

  • Corton Capital reported no remaining Travere Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Corton Capital sold 10,732 Travere Therapeutics shares in Q3 2025, an estimated $159K.
  • Corton Capital first reported a position in Travere Therapeutics in Q4 2021 and held it in 4 quarters.
  • Corton Capital's Travere Therapeutics position peaked at $414K in Q4 2021.
  • 238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.